Investigadores en Pediatría y Neonatología rendimos homenaje a la Dra Virginia Apgar

  1. Gesteiro, Eva 1
  2. Sánchez-Muniz, Francisco J 2
  3. Perea, Sagrario 3
  4. Espárrago, Manuel 4
  5. Bastida, Sara 2
  1. 1 Departamento de Salud y Rendimiento Humano. Facultad de Ciencias de la Actividad Física y del Deporte-INEF. Universidad Politécnica de Madrid. Madrid
  2. 2 Departamento de Nutrición y Ciencia de los Alimentos. Facultad de Farmacia. Universidad Complutense de Madrid. Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC) y Grupo Nutrición y Salud Cardiovascular, UCM, Madrid
  3. 3 Ex-jefa de Servicio de Farmacia. Hospital Virgen de la Salud. Toledo
  4. 4 Servicio de Análisis Clínicos. Hospital de Mérida. Badajoz
Mostrar afiliaciones +
Revista:
Journal of Negative and No Positive Results: JONNPR

ISSN: 2529-850X

Año de publicación: 2019

Volumen: 4

Número: 3

Páginas: 387-397

Tipo: Artículo

DOI: 10.19230/JONNPR.2541 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Journal of Negative and No Positive Results: JONNPR

Objetivos de desarrollo sostenible

Resumen

This short article is a tribute to Doctor Virginia Apgar, one of the great unknown of Medicine. She contributed with her test for measuring vitality at birth to drastically reduce perinatal morbility and  mortality. The Apgar test evaluates five aspects: heart rate, breathing effort, reflexes, muscle tone and skin color at one minute and five minutes after birth. Nowadays, the Apgar test is applied in labor protocols all  over the world. A score <6 at the first minute of life implies the need for energetic resuscitation maneuvers. At 5 minutes of life, the Apgar index has prognostic value, and if the score is <7 indicates the possibility of neurological sequelae. The Apgar index is also used as a fetal distress marker. The paper ends by commenting on some data from the Area of Toledo, La Serena and Mérida studies, where members of  our group have found negative correlation between the Apgar test score, serum glucose and Apolipoprotein  B levels at birth. Future studies are needed to confirm the diagnostic value of this test for those marker alterations at birth. 

Referencias bibliográficas

  • https://www.infobae.com/.../2018/.../07/el-doodle-de-google-recuerda-a-virginia-apgar
  • https://www.bing.com/search?q=Virginia+Apgar+Tuiter&src=IESearchBox&FORM=IE8SRC&pc=EUPP_
  • https://es.wikipedia.org/wiki/Virginia_Apgar. Accessed on 8th June, 2018.
  • Appelgren L. The woman behind the Apgar score. Virginia Apgar. The woman behind the scoring system for quality control of the newborn. Lakartidningen 1991; 88(14):1304-1306.
  • Baskett TF. Virginia Apgar and the newborn Apgar score. Resuscitation 2000; 47(3):215-217.
  • Calmes SH. Virginia Apgar: a woman physician's career, in a developing specialty. J Am Med Women's Assoc 1972; 39(6): 184-188.
  • Frey R, Bendixen H. In memoriam Virginia Apgar 1909-1974. Der Anaesthesist 1977; 26(1): 45.
  • Goodwin JW. A personal recollection of Virginia Apgar. J Obstetrics Gynaecol Canada 2002; 24(3): 248-249.
  • Goldman R, Blickstein I. Dr. Virginia Apgar--1909-1974. Harefuah 2001, 140(2): 177-178.
  • Ignatius J. Virginia Apgar 1909-1974, Duodecim; Lääketieteellinen Aikakauskirja 1993; 109(1): 54-55.
  • James LS. Fond memories of Virginia Apgar. Pediatrics 1975; 55(1): 1-4.
  • James LW. Memories of Virginia Apgar. Teratology 1974; 10(3): 213-15.
  • Kovács J. In commemoration of Virginia Apgar. Orvosi Hetilap 1989; 130(38): 2049-2050.
  • Mazana Casanova JS. Virginia Apgar and her postnatal test half a century later. An Esp Pediatr 2000; 53(5): 469.
  • Morishima HO. Virginia Apgar (1909-1974). J Pediatr 1996; 129(5): 768-770.
  • Shampo MA, Kyle RA. Virginia Apgar--the Apgar score. Mayo Clin Proc 1995; 70(7):680.
  • Schoenberg DG; Schoenberg BS. Eponym: yes, Virginia, there is an Apgar score. South Med J 1977; 70(1): 101.
  • Wilhelmson-Lindell B. Virginia Apgar Award to Petter Karlberg. After 45 years of pioneering commission as a pediatrician, the research on body-soul-environment is tempting. Lakartidningen 1990; 87(40): 3198-200.
  • Videira Amaral JM, Pedro E, Aparicio O, Halpern MJ. Lipoprotein in neonates. En: Lipid metabolism and its pathology. Halpern MJ. (ed). Elsevier Science Publishers B.V. Amsterdam. 1986. pp. 143-147.
  • Bastida S, Perea S, Sánchez-Muniz FJ, Ureta A. Estudio Toledo: riesgo cardiovascular en neonatos y en la población infantil. Acta Pediatr Esp 1993; 51: 643-648.
  • Espárrago M, Bastida S, Sánchez-Muniz FJ. Estudio “La Serena”: Características antropométricas y riesgo cardiovascular futuro de neonatos y niños extremeños. Acta Ped Esp 1999; 57: 259-268.
  • Sánchez-Muniz FJ, Cuesta C, Bastida S, Perea S, Moya P. Perfil lipoproteico en una muestra seleccionada de neonatos a término del Estudio Toledo. An Esp Pediatr 1994; 40: 173-180.
  • Apgar V. A proposal for a new method of evaluation of the newborn infant. Curr Res Anaesth Analg 1953; 32: 260-267.
  • Butterfield LJ. Virginia Apgar, MD, MPhH. Neonatal network: NN 1994; 13(6): 81-83.
  • Cress HR, Shaher RM, Laffin R, Karpovicz K. Cord blood hyperlipoproteinemia and perinatal stress. Pediatr Res 1977; 11: 19-23.
  • Hardell LI. Serum lipids and lipoproteins at birth based on a study of 2815 newborn infants. I. Concentrations and distributions of triglycerides and cholesterol. Acta Paediatr Scand 1981 (Suppl); 285: 5-10.
  • Hardell LI. Serum lipids and lipoproteins at birth based on a study of 2815 newborn infants. II. Relations between materno-fetal factors and the concentrations of triglycerides and cholesterol. Acta Paediatr Scand 1981 (Suppl); 285: 11-20.
  • Perea S. Perfil antropométrico y lipoproteico de los neonatos del estudio "Área de Toledo". Tesis Doctoral. Facultad de Farmacia. Universidad Complutense. Madrid. 1994.
  • Ose L, Iden A, Bakke T, Aarskong D. Neonatal screening for hyperlipidaemia. Postgrad Med J 1975; 51 Suppl. 8: 88-92.
  • Diaz M, Leal C, Ramon y Cajal J, Jimenez MD, Martinez H, Pocovi M, Grande F. Cord blood lipoprotein-cholesterol: relationship birth weight and gestational age of Newborns. Metabolism 1989; 38: 435-438.
  • Andersen GE, Friis-Hansen B. Neonatal diagnosis of familial type II hyperlipoproteinemia. Pediatrics 1976; 57: 214-220.
  • Andersen GE, Friis-Hansen B. Neonatal hypertriglyceridemia: a new index of antepartum-intrapartum fetal stress? Acta Paediatr Scand 1976; 65: 369-374.
  • Potter JM. Perinatal plasma lipid concentrations. Aust Nz J Med 1977; 7: 155-160.
  • Tsang RC, Fallat RW, Glueck C. Cholesterol at birth and age 1: comparison of normal and hypercholesterolemic neonates. Pediatrics 1974; 53: 458-470.
  • Fabiani F, Rodríguez Francés I. Colesterol, triglicéridos y lipoproteínas en sangre de cordón. Relaciones materno-fetales. Rev Esp Pediatr 1984; 40: 199-204.
  • Hales CN, Ozanne SE. For debate: fetal and early postnatal growth restriction lead to diabetes, the metabolic syndrome and renal failure. Diabetologia 2003; 46: 1013-1019.
  • Gesteiro Alejos E. Factores nutricionales, lipoproteicos y hormonales como marcadores precoces de insulinorresistencia y enfermedad cardiovascular en recién nacidos. Tesis Doctoral. Facultad de Farmacia. Universidad Complutense de Madrid. 2015.
  • Kirimi E, Cesur Y, Gül A. Normal levels of insulin, growth hormone and cortisol levels in venous cord blood of healthy fullterm infants: correlation with birthweight and placental weight. Eastern J Med 2000; 6: 14-17.
  • Christou H, Connors JM, Ziotopoulou M, Hatzidakis V, Papathanassoglou E, Ringer SA, Mantzoros CS. Cord blood leptin and insulin-like growth factor levels are independent predictors of fetal growth. J Clin Endocrinol Metab 2001; 86: 935-938.
Fuente de los datos: Dialnet